Predictions
Medigene AG
Start price
Target price
Perf. (%)
€2.69
22.03.24
22.03.24
-
22.03.25
22.03.25
-16.73%
30.03.24
30.03.24
Could be very worthwhile Investment >20% year
Very capable Management
Good culture
Little innovation
Bio-Gate AG
Start price
Target price
Perf. (%)
€1.05
03.02.24
03.02.24
-
03.02.25
03.02.25
1.90%
17.02.24
17.02.24
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Bio-Gate AG
Start price
Target price
Perf. (%)
€1.06
26.12.23
26.12.23
-
26.12.24
26.12.24
-8.96%
11.01.24
11.01.24
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
MorphoSys AG
Start price
Target price
Perf. (%)
€17.06
26.11.23
26.11.23
-
26.11.24
26.11.24
57.74%
09.12.23
09.12.23
Could be worthwhile Investment >10% per year
Drägerwerk AG & Co. KGaA VZO
Start price
Target price
Perf. (%)
€53.60
14.11.23
14.11.23
-
14.11.24
14.11.24
-10.73%
31.01.24
31.01.24
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.95
11.11.23
11.11.23
-
11.11.24
11.11.24
-
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Bio-Gate AG
Start price
Target price
Perf. (%)
€0.81
05.11.23
05.11.23
-
05.11.24
05.11.24
15.43%
11.11.23
11.11.23
Could be worthwhile Investment >10% per year
Top 10 in its market
Very Future proof/growth oriented business model
Significant cyclical dependencies
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€33.12
11.10.23
11.10.23
-
11.10.24
11.10.24
14.79%
12.12.23
12.12.23
Known brand
Could be worthwhile Investment >10% per year
Fresenius Medical Care AG & Co KGaA ST
Start price
Target price
Perf. (%)
€38.99
04.10.23
04.10.23
€22.00
04.10.24
04.10.24
-16.75%
14.10.23
14.10.23
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation